Doctors have hailed 'unprecedented' results from a breakthrough cancer injection that completely eradicated tumours in some patients who had exhausted other treatment options.
Revolutionary Drug Shows Remarkable Success
The triple-action cancer jab, amivantamab, blocked a crucial protein that helps cancers grow, stopped a second pathway tumour cells use to evade treatment, and activated the immune system to attack. In a trial of 102 head and neck cancer patients, 42% saw their tumours shrink, with 15 patients experiencing complete tumour disappearance.
Patient Story: Carl Walsh
Carl Walsh, 56, from Birmingham, was among those whose life was transformed by the treatment. 'I struggled to speak properly and found eating difficult because of the swelling and pain,' he said of his tongue cancer at its worst. After joining the trial at The Royal Marsden hospital, Carl's condition dramatically improved. 'The thing I enjoyed most was the first big steak,' he said, adding: 'I now feel able to live a normal life.'
How the Drug Works
The drug, administered every three weeks, works by blocking crucial proteins that help cancers develop while boosting the immune system's ability to fight the disease. It targets both cancer growth pathways and immune evasion mechanisms, offering a multi-pronged attack.
Expert Reaction
Professor Kevin Harrington from The Institute of Cancer Research said: 'These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy.' The treatment offers hope to thousands of patients facing limited options, with around 12,800 people diagnosed with head and neck cancer in the UK each year.
Key Takeaways
- Triple-action mechanism blocks cancer proteins, evasive pathways, and boosts immunity
- 15 patients saw complete tumour eradication in the trial
- 42% of 102 patients experienced tumour shrinkage
- Drug administered every three weeks
- Offers hope for treatment-resistant cancers
